Industry: Scientific research Region: UK Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
The company is a technology enterprise focusing on the digital compliance management of pharmaceutical and life science supply chain, and is committed to using artificial intelligence to realize the automation of compliance process. The platform developed by the company can digitally manage the supply chain documents, automatically implement the batch review and release process, and support the safety cooperation between different manufacturing entities. Pharmaceutical, medical devices and life science manufacturing networks involve a large number of quality documents, batch records and regulatory requirements. Traditional manual processing methods are inefficient, which is not conducive to cross-enterprise collaboration and continuous meeting of changing regulatory requirements. The platform helps enterprises to improve quality management and operational efficiency and strengthen compliance control in manufacturing network through the functions of document digitization, workflow automation and supply chain collaboration. The company hopes to verify the demand for digital compliance platform in China and Japan, understand the local procurement process, and find local partners, distributors and regulatory consultants to promote the pilot and commercial application of the platform.
Cooperation mode:
At present, the company is looking for a strategic partner in China. The cooperation direction includes the pilot of compliance management platform, digitalization of pharmaceutical and medical device supply chain, channel cooperation, regulatory consultation and marketing. The company hopes to establish cooperative relations with pharmaceutical enterprises, medical equipment enterprises, contract R&D and production enterprises, quality management institutions, software service enterprises and industrial parks in China.